HK1080895A1 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor - Google Patents

Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor

Info

Publication number
HK1080895A1
HK1080895A1 HK06100717A HK06100717A HK1080895A1 HK 1080895 A1 HK1080895 A1 HK 1080895A1 HK 06100717 A HK06100717 A HK 06100717A HK 06100717 A HK06100717 A HK 06100717A HK 1080895 A1 HK1080895 A1 HK 1080895A1
Authority
HK
Hong Kong
Prior art keywords
growth factor
hepatocyte growth
gene
heterotypes
high expression
Prior art date
Application number
HK06100717A
Other languages
English (en)
Inventor
Kim Jong Mook
Park Eun-Jin
Hahn Woong
Yu Seung-Shin
Kim Sunyoung
Original Assignee
Viromed Co Ltd
Beijing Northland Biotech Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd, Beijing Northland Biotech Co filed Critical Viromed Co Ltd
Publication of HK1080895A1 publication Critical patent/HK1080895A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
HK06100717A 2002-03-20 2006-01-17 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor HK1080895A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020020015074A KR100562824B1 (ko) 2002-03-20 2002-03-20 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PCT/KR2003/000548 WO2003078568A2 (en) 2002-03-20 2003-03-20 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor

Publications (1)

Publication Number Publication Date
HK1080895A1 true HK1080895A1 (en) 2006-05-04

Family

ID=28036130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100717A HK1080895A1 (en) 2002-03-20 2006-01-17 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor

Country Status (14)

Country Link
US (5) US7812146B2 (xx)
EP (1) EP1490492B1 (xx)
JP (1) JP4057537B2 (xx)
KR (1) KR100562824B1 (xx)
CN (1) CN100378219C (xx)
AT (1) ATE380826T1 (xx)
AU (1) AU2003210053A1 (xx)
BR (1) BRPI0303570B8 (xx)
DE (1) DE60318026T2 (xx)
DK (1) DK1490492T3 (xx)
ES (1) ES2298538T3 (xx)
HK (1) HK1080895A1 (xx)
PT (1) PT1490492E (xx)
WO (1) WO2003078568A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
KR20080082629A (ko) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 간세포 성장인자 인트론 융합 단백질
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2720611C (en) * 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
EP2216399A1 (en) 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
CN102120047A (zh) * 2010-01-11 2011-07-13 上海优益绩国际贸易有限公司 血运重建基因药物靶向投递缓释支架
MX2016005006A (es) 2013-10-22 2016-07-14 Viromed Co Ltd Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
WO2016048105A1 (ko) * 2014-09-26 2016-03-31 주식회사 바이로메드 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
WO2017135795A1 (ko) * 2016-02-04 2017-08-10 주식회사 에스엘바이젠 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도
CA3086046C (en) * 2017-12-29 2023-02-21 Helixmith Co., Ltd. Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
CN108611367B (zh) * 2018-04-24 2019-11-19 北京诺思兰德生物技术股份有限公司 一类通过质粒载体介导的基因治疗重组载体
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛
CA3106078A1 (en) * 2018-07-17 2020-01-23 Junghun Lee Treatment of neuropathy with dna constructs expressing igf-1 isoforms
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy
CN110747214B (zh) * 2019-03-13 2021-12-31 深圳市臻质医疗科技有限公司 DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法
KR20210035126A (ko) 2021-03-18 2021-03-31 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
KR20220135215A (ko) * 2021-03-29 2022-10-06 주식회사 헬릭스미스 샤르코-마리-투스병 예방 또는 치료용 약제학적 조성물
US20230212603A1 (en) * 2021-10-06 2023-07-06 G&P Bioscience Co., Ltd. Development of optimized recombinant expression construct

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) * 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
EP0539590B1 (en) * 1990-07-13 1999-03-31 Snow Brand Milk Products Co., Ltd. Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
WO1997007824A1 (fr) * 1995-08-29 1997-03-06 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprenant le gene hgf
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
EA005157B1 (ru) 1997-05-06 2004-12-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов
JPH11246433A (ja) 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
WO1999045775A1 (en) 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
WO2000007615A1 (fr) * 1998-08-05 2000-02-17 Sumitomo Pharmacueticals Co., Ltd. Preparations destinees a l'administration d'un facteur de croissance des hepatocytes
CA2356701C (en) * 1999-10-29 2011-02-15 Ryuichi Morishita Gene therapy for diabetic ischemic disease
JP2003513942A (ja) 1999-11-05 2003-04-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ遺伝子送達による心血管疾患を処理するための技術および組成物
CN1142272C (zh) * 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
ATE530197T1 (de) * 2000-06-27 2011-11-15 Anges Mg Inc Medizinische zusammensetzungen zur angiogenese- therapie
CA2433936A1 (en) * 2001-01-23 2002-08-22 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
AU2006244639A1 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2720611C (en) 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna

Also Published As

Publication number Publication date
KR20030075718A (ko) 2003-09-26
WO2003078568A2 (en) 2003-09-25
BRPI0303570B1 (pt) 2018-04-24
US20050079581A1 (en) 2005-04-14
CN1643149A (zh) 2005-07-20
ES2298538T3 (es) 2008-05-16
KR100562824B1 (ko) 2006-03-23
WO2003078568A3 (en) 2003-11-27
DE60318026D1 (de) 2008-01-24
ATE380826T1 (de) 2007-12-15
BR0303570A (pt) 2005-07-19
DK1490492T3 (da) 2008-03-17
EP1490492A2 (en) 2004-12-29
US20120010273A1 (en) 2012-01-12
US7838505B2 (en) 2010-11-23
JP4057537B2 (ja) 2008-03-05
US8338385B2 (en) 2012-12-25
JP2005520512A (ja) 2005-07-14
US20090131350A1 (en) 2009-05-21
PT1490492E (pt) 2008-03-25
EP1490492A4 (en) 2006-05-31
USRE48404E1 (en) 2021-01-26
BRPI0303570B8 (pt) 2021-05-25
US7745174B2 (en) 2010-06-29
EP1490492B1 (en) 2007-12-12
CN100378219C (zh) 2008-04-02
DE60318026T2 (de) 2008-11-20
AU2003210053A8 (en) 2003-09-29
US20100105878A1 (en) 2010-04-29
US7812146B2 (en) 2010-10-12
AU2003210053A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
HK1080895A1 (en) Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
ATE291616T1 (de) Neue carbonyl-reduktase, gen davon und verfahren der anwendung derselben
DE69731834D1 (de) Agouti verwandtes gen
EA200600746A1 (ru) Конструкции нуклеиновых кислот
ATE293696T1 (de) Mutierte alpha-amylase enzyme mit erhöhter stabilität
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
DE60031419D1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
EP1546174A4 (en) METHOD AND COMPOSITIONS FOR RNA INTERFERENCE
DE60030988D1 (de) Verfahren zur Herstellung Von L-Aminosäuren durch Erhöhung des zellulären NADPH
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
ATE334199T1 (de) Modifizierte faktor viii cdna
EP1548107A4 (en) CHROMOPROTEIN AND FLUOROPROTEINS
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
AU2099301A (en) Method for obtaining proteins having improved functional characteristics
AU2002307510A1 (en) Cytokine protein family
ATE231518T1 (de) Ribonukleosid-derivat und verfahren zu seiner herstellung
HK1038572A1 (en) Growth differentiation factor promoter and uses therefor
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
MXPA05006983A (es) Promotor artificial para la expresion de secuencias de acido desoxirribonucleico en celulas vegetales.
ATE408415T1 (de) Inhibitoren für die gefässneubildung
ATE310823T1 (de) Expressionssystem zur produktion von proteinen in pilzen
ATE292675T1 (de) Tetrahydropyrimidin-dioxygenase-gen, dadurch kodierte polypeptide und verfahren zur deren herstellung
WO2003061581A3 (en) Compositions and methods for regulating rna stability using polypyrimidine tract proteins
ATE278784T1 (de) Polypeptide

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230316